SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to heightened attention surrounding the company's new commercial, with community members sharing their excitement after spotting it during NFL games and on YouTube. Despite positive reactions to the advertisement, some investors remain concerned about the stock's performance following the recent reverse split and broader challenges within the EV sector. Discussions also encompass perspectives on the company's long-term viability and potential for a short squeeze.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to news of a closed $100M private placement and the launch of an Injective (INJ) digital asset treasury strategy, making it the first public company to hold INJ tokens. The community is actively discussing potential short squeezes and high volatility, while others caution about dilution. With a small float and high borrow costs, the stock has seen significant price swings, leading to both bullish and bearish sentiments.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent momentum and growing number of watchers, with many highlighting upcoming utilities. Community members are expressing bullish sentiment, anticipating further gains and airdrops for NFT holders. The conversation also reflects excitement around staking and the project's overall development.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Traders are actively discussing GYRO due to its low float and potential for a significant price surge, with some highlighting a key breakout level that could trigger further momentum. Community members are also pointing to the company's underlying assets and liquidation strategy, suggesting the stock is undervalued. The stock is gaining increased attention, with many hoping to capitalize on a potential parabolic run.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending downwards after reports surfaced linking Tylenol use during pregnancy to autism, sparking concerns about potential liabilities and revenue impact. The community is debating the validity of these claims and the potential for a buying opportunity amidst the uncertainty, while some traders are taking a cautious stance due to headline risk and recent revenue misses.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending as community members highlight bullish chart patterns and anticipate a breakout, with some mentioning its connection to the Shiba Inu ecosystem. Discussions center around accumulation, strong support, and potential for significant upward movement. Some users are comparing it to other meme coins and highlighting its potential for charity burns.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its inclusion in the S&P 500, sparking enthusiastic discussions around the potential for increased visibility and ETF buying.  While some community members are optimistic about continued momentum, others caution that the stock may be overvalued and due for a correction.  The inclusion highlights AppLovin's growth in the ad tech space, but also invites debate about long-term performance following index additions.

RedStone Is The Fastest Growing oracle, specialising in yield-bearing collateral for lending markets and securing $10bn+ . Blue chip DeFi protocols are our clients including Spark, Morpho, Compound, Pendle, Venus, Lido, EtherFi, Ethena, Puffer, Balancer, Lombard, Enzyme, Frax, Agora, M^0 and 80+ other Clients. RedStone provides a wide variety of in-demand assets such as LSTs, LRTs, Bitcoin LSTs and many others.

RedStone

RedStone ($RED.X) is trending as the community discusses its potential as an alternative to Chainlink, focusing on its transaction speeds and TVS/marketcap ratio. Some community members are pointing out its strong price action versus Bitcoin and Etherium. Others are noting that the price momentum may be cooling off in the short term.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond Inc ($BBBY) is trending as traders discuss its potential, blockchain assets, and comparisons to meme stock phenomena like $GME.  The community is weighing in on whether the ticker's return signals a short squeeze opportunity or reflects Overstock's rebranding strategy, with some drawing comparisons to past rallies.  Speculation is also fueled by discussion of Ryan Cohen's possible involvement and the company's blockchain initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results 

CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.

Company News for Sep 3, 2025

Companies In The News Are: SIG, PEP, CYTK, AL.

Retail chatter around Cytokinetics surged late&nbsp;Monday&nbsp;as the company’s shares jumped 34% in Europe after new data from its MAPLE-HCM study were presented at the European Society of Cardiology Congress 2025 in Madrid.Cytokinetics’ shares closed at €39.8 on Monday in Europe, up €10, or 33.6% from the prior session.The company stated that its experimental drug, aficamten, improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy, whereas treatment with the current standard of care, metoprolol, reduced it.The primary results were also published in The New England Journal of Medicine.MAPLE-HCM is a Phase 3 randomized, double-blind, active-comparator trial that enrolled 175 patients, who were assigned one-to-one to receive either aficamten or metoprolol as monotherapy.&nbsp;Cytokinetics said the trial was designed differently from its pivotal SEQUOIA-HCM study, enrolling patients with less severe disease, including those without obstruction at rest and with higher predicted peak oxygen uptake.Fady I. Malik, executive vice president of research and development, said the clinical difference between the two treatments was reinforced by secondary endpoints on symptoms, functional class and left ventricular outflow tract (LVOT) gradients, and that the benefits were seen in a broader patient population than in SEQUOIA-HCM.Cytokinetics also presented additional data from MAPLE-HCM at the ESC Congress, including a pre-specified analysis of aficamten’s effect on cardiac structure and function, published in the Journal of the American College of Cardiology.&nbsp;A late-breaking clinical science presentation on the incidence and impact of atrial fibrillation associated with aficamten was simultaneously published in Heart Rhythm.“The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of aficamten, including as has been observed with a real-world dosing strategy,” Malik said.&nbsp;On Stocktwits, retail sentiment for Cytokinetics was ‘extremely bullish’ amid a 150% surge in 24-hour message volume.One user stated that Cytokinetics appeared to be a clear buyout candidate, citing its head-to-head superiority over the standard-of-care metoprolol.<stembedurl>https://stocktwits.com/lebranjames/message/627145099</stembedurl>Another user noted that while Cytokinetics had strong data, it would still require significant funding, partnerships, and guideline updates before its drug could replace beta blockers, although they expected the stock to trade higher next week.&nbsp;<stembedurl>https://stocktwits.com/John62/message/627141611</stembedurl><a href="https://stocktwits.com/symbol/CYTK">Cytokinetics’ stock</a> has declined 25% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cytokinetics’ stock (CYTK) has declined 25% so far in 2025. (Photo credit: Getty Images)

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough 

The company unveiled Phase 3 MAPLE-HCM results showing aficamten outperformed metoprolol in obstructive hypertrophic cardiomyopathy, with findings published across top medical journals.

Equity

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Beats Q4 Earnings and Revenue Estimates

Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK, Jan...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.58	--	--	N/A
Q2 '25	-$1.43	-$1.12	21.66%	BEAT
Q1 '25	-$1.37	-$1.36	0.68%	BEAT
Q4 '24	-$1.19	-$1.26	-5.61%	MISSED
Q3 '24	-$1.23	-$1.36	-10.16%	MISSED

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest CYTK News

CYTK Cytokinetics Inc